Amerikanische Gesellschaft für Hirudotherapie

Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach.

Review published in Current opinion in rheumatology (2023)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienArzneimittelentwicklungAmbati et al. · Current opinion in rheumatology, 2023

Abstract

PURPOSE OF REVIEW: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease that has morbid and sometimes devastating effects on patients and their families. This review will discuss the most recent international societal treatment guidelines and propose practical management algorithms for various APS sub-types. RECENT FINDINGS: APS represents a disease spectrum. Although thrombosis and pregnancy morbidities are traditional hallmarks of APS, a variety of extra-criteria clinical phenotypes can often be seen, which makes clinical management more challenging. Primary APS thrombosis prophylaxis should take a risk-stratified approach. Although vitamin K antagonists (VKAs) or heparin/low molecular weight heparin (LMWH) remain the preferred treatment for secondary APS thrombosis prophylaxis, some international society guidelines support the use of direct oral anticoagulants (DOACs) in certain circumstances. Careful monitoring and individualized obstetric care with the use of aspirin and heparin/LMWH will improve pregnancy outcomes among pregnant individuals with APS. Treatment of microvascular and catastrophic APS remains challenging. While the addition of various immunosuppressive agents is often utilized, further systemic evaluations of their use are warranted before definitive recommendations can be made. Several new therapeutic strategies are on the horizon that might enable more personalized and targeted APS management in the near future. SUMMARY: Although the knowledge of APS pathogenesis has grown in recent years, the management principles and strategies are largely unchanged. There is an unmet need for evaluating pharmacological agents, beyond anticoagulants, that target diverse thromboinflammatory pathways.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeReviewJournal ArticleResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov't
Indexed MeSH termsPregnancyFemaleHumansAntiphospholipid SyndromeHeparin, Low-Molecular-WeightAnticoagulantsAspirinThrombosis

Zusammenfassung

Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease that has morbid and sometimes devastating effects on patients and their families. This review will discuss the most recent international societal treatment guidelines and propose practical management algorithms for various APS sub-types.

Warum dies für die Hirudotherapie relevant ist

This review discusses international societal treatment guidelines for antiphospholipid syndrome (APS) and proposes practical management algorithms for various APS subtypes, including thrombosis prophylaxis, pregnancy management, and catastrophic APS. Vitamin K antagonists and heparin/LMWH remain preferred treatments for secondary thrombosis prophylaxis, with some guidelines supporting direct oral anticoagulants in select cases; the review also highlights unmet needs for therapies targeting thromboinflammatory pathways beyond anticoagulants. The abstract does not mention leeches, hirudotherapy, hirudin, or any leech-derived therapy. Its relevance to ASH is absent, as the review focuses entirely on conventional and emerging pharmacological approaches to APS without engaging any leech-related intervention.

Zitation

Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach.

Ambati et al. · Current opinion in rheumatology, 2023

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.